Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

CC BY-NC-ND 4.0 · Thromb Haemost 2018; 118(11): e1-e2
DOI: 10.1055/s-0039-3400530

Erratum

Derek Weycker

¹Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States

,

Xiaoyan Li

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

,

Gail DeVecchis Wygant

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

,

Theodore Lee

³Pfizer Inc., New York, New York, United States

,

Melissa Hamilton

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

,

Xuemei Luo

⁴Pfizer Inc., Groton, Connecticut, United States

,

Lien Vo

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

,

Jack Mardekian

³Pfizer Inc., New York, New York, United States

,

Xianying Pan

⁵Bristol-Myers Squibb, Wallingford, Connecticut, United States

,

Leah Burns

²Bristol-Myers Squibb, Lawrenceville, New Jersey, United States

,

Mark Atwood

¹Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States

,

Ahuva Hanau

¹Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States

,

Alexander T. Cohen

⁶Guy's and St. Thomas' Hospitals, London, United Kingdom